Niagen Bioscience, Inc. (NAGE) stock
Close on Nov 12, 2026Market cap $168.93MP/E 17.8Yield –
Niagen Bioscience, Inc. saw revenue fall 1.9% to $122.29M over the twelve months to Sep 30, 2026. Operating income fell 75.3% to $4.78M, moving the operating margin from 15.5% to 3.9%. At the latest close the market valued the company at $168.93M, 17.8 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $168.93M
- P/E ratio
- 17.8
- Price to sales
- 1.38
- Price to book
- 2.03
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $122.29M
- Net income
- $10.24M
- EPS, diluted
- $0.12
- Book value per share
- $1.05
- Diluted shares
- 79M
Trading
- Next earnings
- Mar 3, 2027 (estimated, during market hours)
- Previous close
- $2.10
- Open
- $2.10
- Day's range
- $2.06 – $2.14
- Volume
- 515,243
- Average volume (20 days)
- 550,889
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- 1.05
- 52-week range
- $2.04 – $7.28
- RSI (14 days)
- 37.6
- Volatility (1 year)
- 50.6%
- Relative volume
- 0.89×
- WACC
- 10.2%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | NAGE | S&P 500 | Difference | NAGE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -18.8% | -2.7% | −16.1 pts | ||
| 3 months | -30.2% | -1.7% | −28.5 pts | ||
| Year to date | -66.4% | +11.9% | −78.3 pts | ||
| 1 year | -70.3% | +12.0% | −82.3 pts | ||
| 3 years | +55.8% | +78.2% | −22.3 pts | +15.9% | +21.2% |
| 5 years | -65.2% | +73.2% | −138.4 pts | -19.0% | +11.6% |
| 10 years | -28.4% | +309.6% | −338.0 pts | -3.3% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Niagen Bioscience filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- Results
About Niagen Bioscience
Medicinal Chemicals & Botanical Products
Niagen Bioscience, Inc. is a global bioscience company dedicated to healthy aging through research and commercialization of nicotinamide adenine dinucleotide (NAD+) precursors. Its business includes consumer products, ingredients, analytical reference standards and services, and a pre-revenue pharmaceutical development segment. The consumer segment markets dietary supplements under the Tru Niagen brand directly to consumers online, through retail marketplaces, and via distribution partners. Its ingredients segment supplies proprietary food-grade Niagen (nicotinamide riboside chloride) to consumer product manufacturers and pharmaceutical-grade Niagen to FDA-registered 503B outsourcing facilities and compounding pharmacies for prescription injectables.
Company profile, executives and historyNiagen Bioscience stock: common questions
What is Niagen Bioscience's stock price?
NAGE closed at $2.13 on Nov 12, 2026, up 1.91% on the day. Over the past 52 weeks it traded between $2.04 and $7.28.
What is Niagen Bioscience's market cap?
Niagen Bioscience was worth $168.93M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is NAGE's P/E ratio?
NAGE trades at 17.8 times earnings, based on diluted earnings per share of $0.12 over the twelve months to Sep 30, 2026.
How much revenue does Niagen Bioscience make?
Niagen Bioscience reported revenue of $122.29M for the twelve months to Sep 30, 2026, down 1.9% from a year earlier.
Does Niagen Bioscience pay a dividend?
No. Niagen Bioscience has not paid a cash dividend over the last twelve months.
When does Niagen Bioscience report earnings next?
Niagen Bioscience is expected to report Q4 FY2026 results on Mar 3, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has NAGE stock performed over the past year?
Including dividends, NAGE returned -70.3% over the past year, against +12.0% for the S&P 500.
How many NAGE shares are sold short?
4M shares were sold short at the latest FINRA report, 5.79% of the float, or 8.9 days of average trading volume.
Who are Niagen Bioscience's competitors?
Companies most similar to Niagen Bioscience by business, industry and size include NAII, MTEX, FTLF, LFVN, BTMD.
See a number that looks wrong?